EGLN3 Antibody

說明書

中文名稱：

EGLN3兔多克隆抗體
貨號：

CSB-PA040512
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA040512(EGLN3 Antibody) at dilution 1/30, on the right is treated with fusion protein. (Original magnification: ×200)
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關產(chǎn)品
靶點詳情

產(chǎn)品詳情

Uniprot No.：

Q9H6Z9
基因名：

EGLN3
別名：

Egl 9 family hypoxia inducible factor 3 antibody; Egl nine homolog 3 (C. elegans) antibody; Egl nine homolog 3 antibody; Egl nine like protein 3 isoform antibody; EGL9 homolog of C. elegans 3 antibody; EGLN3 antibody; EGLN3_HUMAN antibody; Factor responsive smooth muscle protein antibody; HIF Prolyl Hydroxylase 3 antibody; HIF-PH3 antibody; HIF-prolyl hydroxylase 3 antibody; HIFP4H3 antibody; HIFPH3 antibody; HPH-1 antibody; HPH-3 antibody; Hypoxia-inducible factor prolyl hydroxylase 3 antibody; P4H3 antibody; PHD3 antibody; Prolyl Hydroxylase Domain Containing Protein 3 antibody; Prolyl hydroxylase domain-containing protein 3 antibody; SM20 antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human EGLN3
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:5000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as PKM, TELO2, ATF4 and HIF1A. Target proteins are preferentially recognized via a LXXLAP motif. Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF2A. Hydroxylation on the NODD site by EGLN3 appears to require prior hydroxylation on the CODD site. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. ELGN3 is the most important isozyme in limiting physiological activation of HIFs (particularly HIF2A) in hypoxia. Also hydroxylates PKM in hypoxia, limiting glycolysis. Under normoxia, hydroxylates and regulates the stability of ADRB2. Regulator of cardiomyocyte and neuronal apoptosis. In cardiomyocytes, inhibits the anti-apoptotic effect of BCL2 by disrupting the BAX-BCL2 complex. In neurons, has a NGF-induced proapoptotic effect, probably through regulating CASP3 activity. Also essential for hypoxic regulation of neutrophilic inflammation. Plays a crucial role in DNA damage response (DDR) by hydroxylating TELO2, promoting its interaction with ATR which is required for activation of the ATR/CHK1/p53 pathway. Also mediates hydroxylation of ATF4, leading to decreased protein stability of ATF4.
基因功能參考文獻：
1. PHD3 overexpression may reduce the migratory and invasive capacity of gastric cancer cells, and inhibit the formation of tumor vasculature via negatively regulating HIF1A, which has been revealed to control VEGF transcription. PMID: 28901473
2. provides a rationale for targeting the PHD3-mediated regulation of the adaptive cellular hypoxic response in MM and suggests that targeting the O2-sensing pathway, alone or in combination with other anti-myeloma chemotherapeutics, may have clinical efficacy PMID: 29206844
3. These results indicate that the immunohistochemistry analysis of the protein expression of PDK1, PHD3, and HIF-1alpha defines the hypoxic status of Neuroblastoma tumors. PMID: 29117193
4. These findings indicate that downregulation of PHD3 and FIH in HCC is associated with more aggressive tumor behavior and a poor prognosis in hepatocellular carcinoma PMID: 28099905
5. PHD3 loss in cancer enables metabolic reliance on fatty acid oxidation via deactivation of ACC2. PMID: 27635760
6. demonstrate that downregulation of PHD3 augments metastatic spread in human colorectal cancer and identify MCL-1 as a novel downstream effector of oxygen sensing PMID: 26921340
7. In pancreatic Beta cells, knock-down of PHD3 inhibited glucose-stimulated insulin secretion. PMID: 26997627
8. Loss of PHD3 expression is associated with breast cancer. PMID: 26372732
9. The selective efficacy of PZ was further demonstrated at the cellular level by observing inhibition of the PHD3-dependent DNA damage response pathway without stabilization of HIF-1alpha. PMID: 26940742
10. The enhanced expression of PHD3 might likely contribute to the poor neovascularization and affect the biological characterization in PDAC cancer cells PMID: 25542265
11. The data demonstrates that PHD3 can drive cell cycle entry at the G1/S transition through decreasing the half-life of p27 that occurs by attenuating p27S10 phosphorylation. PMID: 26223520
12. PHD3 controls EGFR activity by acting as a scaffolding protein that associates with the endocytic adaptor Eps15 and promotes the internalization of EGFR. PMID: 25420589
13. PHD3 loss sustains cell proliferation through the control of EGFR. PMID: 25420773
14. PHD3 SUMOylation occurs at a cluster of four lysines at the C-terminal end of the protein. Furthermore, PHD3 SUMOylation by SUMO2 or SUMO3 contributes to PHD3-mediated repression of HIF1-dependent transcriptional activity. PMID: 25380826
15. HIFPH3 expression in human non-small cell lung cancer lesions is significantly higher than that in para-cancerous and normal lung tissues and is positively associated with lymph node metastasis and microvessel density. PMID: 25081707
16. A novel role for PHD3 as a negative regulator of cell motility through posttranslational modification of nonmuscle actins. PMID: 25079693
17. LOw expression of PHD3 is associated with gastric cancer. PMID: 23533015
18. PHD3 depletion did not affect the expression of the PDH-E1alpha, E1beta, and E2 subunits, or the phosphorylation status of E1alpha, but destabilized the PDH complex (PDC), resulting in less functional PDC. PMID: 25088999
19. the relationship between PHD3 expression and epithelial-to-mesenchymal transition PMID: 24367580
20. reduced PHD3 expression in cancerous tissue was accompanied by methylation of the CpG rich region located within the first exon and intron of the PHD3 gene. PMID: 24195777
21. PHD3 has an antiproliferative function independent of HIF protein status in renal cell carcinoma (RCC), indicating a novel expression mechanism and function of PHD3. PMID: 24477694
22. Studies suggest that hypoxia, HIF-1 alpha, PHD3 and pVHL could be considered as potential therapeutic targets for lung cancer pathogenesis and progression. PMID: 23601303
23. PHD-3 mediates specific HIF1-alpha proline 567 hydroxylation, which can function as a new player in the VHL/HIF-1alpha interactions. PMID: 23886708
24. The data demonstrate p62 is a critical regulator of the hypoxia response and PHD3 activity, by inducing PHD3 aggregation and degradation under normoxia. PMID: 23345396
25. EGLN3 inhibits cIAP1-mediated IKK-gamma ubiquitination by interfering with the interaction between IKK-gamma and cIAP1. PMID: 23732909
26. Overexpression of PHD3 is a favorable prognosticator for gastric cancer. PMID: 22290580
27. Our study has provided preliminary materials and data for further investigation of the effect of PHD3 on HepG2 cells PMID: 22898032
28. Prolyl hydroxylase 3 (PHD3) modulates catabolic effects of tumor necrosis factor-alpha (TNF-alpha) on cells of the nucleus pulposus through co-activation of nuclear factor kappaB (NF-kappaB)/p65 signaling. PMID: 22948157
29. Egln3 suppresses glioma progression PMID: 22905089
30. identification of HCLK2 as a substrate of PHD3 reveals the mechanism through which hypoxia inhibits the DDR, suggesting hydroxylation of HCLK2 is a potential therapeutic target for regulating the ATR/CHK1/p53 pathway PMID: 22797300
31. These results indicate that EGLN3 gene expression in macrophages is dependent on activin A PMID: 22778395
32. PHD3 may be an important regulator of apoptosis and it is mainly found in tumors with good prognosis. PMID: 21877141
33. a block in G1 to S transition in carcinoma cells under PHD3 inhibition PMID: 22087251
34. High tumor cell expression of PHD3 (P= 0.058) and FIH (P= 0.15) did not, however, reach statistical significance PMID: 21887331
35. The oxygen sensor PHD3 limits glycolysis under hypoxia via direct binding to pyruvate kinase PMID: 21483450
36. these results suggest that PHD3 targets Pax2 for destruction. PMID: 21575608
37. Interaction of PKM2 with prolyl hydroxylase 3 (PHD3) enhances PKM2 binding to HIF-1alpha and PKM2 coactivator function; PKM2 participates in a positive feedback loop that promotes HIF-1 transactivation and reprograms glucose metabolism in cancer cells. PMID: 21620138
38. PHD3 expression is silenced by aberrant CpG methylation in a subset of human carcinoma cell lines of diverse origin and this aberrant cytosine methylation status is the mechanism by which these cancer cell lines fail to upregulate PHD3 mRNA PMID: 21297970
39. Prolyl hydroxylases (PHD3) regulate the transcriptional activity of HIF-1alpha. This could be potentially inhibited by polynitrogen compounds. PMID: 21421125
40. PHD3 has a role in regulating neutrophil survival in hypoxia PMID: 21317538
41. Essential functions of PHD3 in pncreatic tumour growth, apoptosis and angiogenesis. PMID: 20978507
42. hPRP19 interacts with PHD3 to suppress the cell death under hypoxic conditions by limiting the function of PHD3 which leads to caspase activation PMID: 20599946
43. The CpG island of EGLN3 is frequently methylated in plasma cell dyscrasias and B-cell lymphomas. loss of EGLN3 is an important epigenetic event not only in plasma cell neoplasias but also in B-cell neoplasias. PMID: 19737309
44. PHD3 appears to be a tumor suppressor in colorectal cancer cells that inhibits IKKbeta/NF-kappaB signaling, independent of its hydroxylase activity. PMID: 19786027
45. siRNA targeted degradation of HIF-1alpha and HIF-2alpha results in decreased hypoxia-induced PHD3 expression PMID: 15156561
46. results indicate that PHD3 is a TRiC substrate, providing another step at which PHD3 activity may be regulated PMID: 15251459
47. EglN3 acts downstream of c-Jun and is specifically required among the three EglN family members for neuronal apoptosis. PMID: 16098468
48. Mechanism underlying the regulation of PHD3 availability and activity in hypoxia by the E3 ligase Siah2. PMID: 16958618
49. The role of Siah2 phosphorylation in the regulation of its activity toward PHD3 is reported. PMID: 17003045
50. PHD-dependent oxygen-sensing recruits both the hypoxia-inducible factor (HIF) and ATF-4 systems. PMID: 17684156
顯示更多

收起更多
亞細胞定位：

Nucleus. Cytoplasm.
組織特異性：

Widely expressed at low levels. Expressed at higher levels in adult heart (cardiac myocytes, aortic endothelial cells and coronary artery smooth muscle), lung and placenta, and in fetal spleen, heart and skeletal muscle. Also expressed in pancreas. Locali
數(shù)據(jù)庫鏈接：

HGNC: 14661

OMIM: 606426

KEGG: hsa:112399

STRING: 9606.ENSP00000250457

UniGene: Hs.135507

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human